Tag Archives: Debjit Chattopadhyay

H.C. Wainwright Initiates a Buy Rating on Precision BioSciences Inc (DTIL)

H.C. Wainwright analyst Debjit Chattopadhyay initiated coverage with a Buy rating on Precision BioSciences Inc (DTIL – Research Report) today and set a price target of $21. The company’s shares closed yesterday at $13.76. Chattopadhyay wrote: “Our $21 price target

Analysts Offer Insights on Healthcare Companies: Amicus (NASDAQ: FOLD) and Y-Mabs Therapeutics Inc (NASDAQ: YMAB)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amicus (FOLD – Research Report) and Y-Mabs Therapeutics Inc (YMAB – Research Report) with bullish sentiments. Amicus (FOLD) In a report released

Analysts’ Top Healthcare Picks: Global Blood Therapeutics (GBT), Genfit SA (GNFT)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Global Blood Therapeutics (GBT – Research Report), Genfit SA (GNFT – Research Report) and Minerva Neurosciences (NERV – Research Report) with bullish

H.C. Wainwright Believes Galapagos NV (NASDAQ: GLPG) Still Has Room to Grow

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Galapagos NV (GLPG – Research Report) today and set a price target of $150. The company’s shares closed yesterday at $122.75, close to its 52-week high of $125.48. Chattopadhyay commented:

Analysts Offer Insights on Healthcare Companies: Homology Medicines Inc (NASDAQ: FIXX) and Sesen Bio Inc (NASDAQ: SESN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Homology Medicines Inc (FIXX – Research Report) and Sesen Bio Inc (SESN – Research Report) with bullish sentiments. Homology Medicines Inc (FIXX)

H.C. Wainwright Keeps a Buy Rating on Sutro Biopharma Inc (STRO)

H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on Sutro Biopharma Inc (STRO – Research Report) today and set a price target of $18. The company’s shares closed yesterday at $10.15. Chattopadhyay said: “Valuation and risks to our investment